Top 10 Growth Stocks To Own For 2019

Wall Street brokerages expect Radware (NASDAQ:RDWR) to report earnings per share (EPS) of $0.08 for the current quarter, according to Zacks. Four analysts have issued estimates for Radware’s earnings, with estimates ranging from $0.07 to $0.08. Radware reported earnings per share of $0.03 during the same quarter last year, which suggests a positive year-over-year growth rate of 166.7%. The company is expected to announce its next earnings report on Wednesday, August 1st.

On average, analysts expect that Radware will report full year earnings of $0.35 per share for the current fiscal year, with EPS estimates ranging from $0.30 to $0.40. For the next financial year, analysts expect that the company will post earnings of $0.51 per share, with EPS estimates ranging from $0.42 to $0.65. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Radware.

Top 10 Growth Stocks To Own For 2019: MEDIFAST INC(MED)

Advisors’ Opinion:

  • [By Max Byerly]

    McCormick & Company, Incorporated (NYSE: MKC) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

  • [By Ethan Ryder]

    MediBloc [MED] (CURRENCY:MED) traded down 11.7% against the U.S. dollar during the 1 day period ending at 21:00 PM Eastern on September 2nd. One MediBloc [MED] token can now be bought for approximately $0.0066 or 0.00000100 BTC on popular cryptocurrency exchanges including Coinrail, Bibox and Gate.io. During the last week, MediBloc [MED] has traded down 27.6% against the U.S. dollar. MediBloc [MED] has a total market cap of $19.63 million and approximately $281,103.00 worth of MediBloc [MED] was traded on exchanges in the last 24 hours.

  • [By Ethan Ryder]

    MediBloc (CURRENCY:MED) traded 3.9% lower against the U.S. dollar during the 1-day period ending at 20:00 PM E.T. on June 13th. One MediBloc token can now be purchased for $0.0083 or 0.00000131 BTC on major cryptocurrency exchanges including Coinrail, Gate.io and Bibox. During the last seven days, MediBloc has traded 36.5% lower against the U.S. dollar. MediBloc has a total market cap of $24.58 million and $216,935.00 worth of MediBloc was traded on exchanges in the last day.

  • [By Lisa Levin]

    Medifast, Inc. (NYSE: MED) shares were also up, gaining 25 percent to $124.60 after the company reported strong Q1 results and raised its FY18 guidance.

  • [By Logan Wallace]

    MediBloc [QRC20] (MED) is a proof-of-work (PoW) token that uses the HybridScryptHash256 hashing algorithm. It was first traded on January 3rd, 2014. MediBloc [QRC20]’s total supply is 4,097,545,844 tokens and its circulating supply is 2,966,384,100 tokens. MediBloc [QRC20]’s official website is medibloc.org/en. MediBloc [QRC20]’s official Twitter account is @MEDDevTeam. The official message board for MediBloc [QRC20] is medium.com/@MediBloc. The Reddit community for MediBloc [QRC20] is /r/MediBloc and the currency’s Github account can be viewed here.

  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings.
    Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share.
    California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings.
    Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results.
    Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter.
    Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results.
    Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results.
    B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings.
    HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings.
    Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r

Top 10 Growth Stocks To Own For 2019: TrueBlue Inc.(TBI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Trueblue (TBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

  • [By Joseph Griffin]

    Trueblue Inc (NYSE:TBI) has received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.50.

  • [By Stephan Byrd]

    Russell Investments Group Ltd. grew its stake in Trueblue Inc (NYSE:TBI) by 21.2% during the first quarter, HoldingsChannel reports. The fund owned 137,178 shares of the business services provider’s stock after purchasing an additional 23,951 shares during the quarter. Russell Investments Group Ltd.’s holdings in Trueblue were worth $3,553,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Trueblue Inc (NYSE:TBI) by 18.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,550 shares of the business services provider’s stock after purchasing an additional 4,700 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Trueblue were worth $823,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Logan Wallace]

    Media stories about Trueblue (NYSE:TBI) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trueblue earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the business services provider an impact score of 45.3296498009881 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Top 10 Growth Stocks To Own For 2019: Nordstrom Inc.(JWN)

Advisors’ Opinion:

  • [By Adam Levine-Weinberg]

    On the other hand, comp sales declined at the struggling Lord & Taylor chain, which again failed to keep up with top rival Nordstrom (NYSE:JWN). Comp sales rose 0.7% for Nordstrom’s full-line business last quarter. The Saks OFF 5TH off-price chain struggled, too, with comp sales down 3.5%. (Nordstrom Rack has also had a rough time lately, but it eked out a 0.4% comp sales gain in Q1.) Lastly, Hudson’s Bay’s European operations had another awful quarter, as comp sales plunged 6.6%.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Nordstrom (JWN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By John Ballard]

    However, whether because of the tax act passed late last year, or something else, consumers are starting to shop again. And that is starting to benefit traditional department stores like Nordstrom (NYSE:JWN) and Macy’s (NYSE:M). Both retailers have posted growth in comparable-store sales and have a strategy to increase their business online, where more people are choosing to shop.

Top 10 Growth Stocks To Own For 2019: Intuitive Surgical Inc.(ISRG)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Medical device makers were some of the best-performing companies on the market last year. In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi talk about three medical device monopolies that investors might want to take a closer look at. Listen and find out what makes Intuitive Surgical (NASDAQ:ISRG), Abiomed (NASDAQ:ABMD), and NovoCure (NASDAQ:NVCR) stand out from the crowd, dominate their niches, and improve patient lives. Plus, learn the key metrics investors should watch, what long-term risks to be aware of, which of the companies faces the most competitive risk, some of the most exciting opportunities still ahead, and more.

  • [By Danny Vena]

    Robotic surgery pioneer Intuitive Surgical (NASDAQ:ISRG) has been a big winner, up 38% since the beginning of the year. Two companies that haven’t been so fortunate are footwear maker Skechers (NYSE:SKX) and flooring retailer Tile Shop Holdings (NASDAQ:TTS), which have fallen 18% and 13% year to date, respectively. Here are some key metrics to watch when these companies report earnings in July.

  • [By Keith Speights]

    But that doesn’t mean such stocks don’t exist. Intuitive Surgical (NASDAQ:ISRG) stands out as one stock that investors should be able to buy and never sell. Here are 12 reasons why.

  • [By Anders Bylund]

    Shares of Intuitive Surgical (NASDAQ:ISRG) rose 10.2% in August 2018, according to data from S&P Global Market Intelligence. The maker of the da Vinci robotic surgery platform and its associated tools didn’t need any actual news to keep its impressive market momentum going.

  • [By Brian Stoffel]

    That’s because these three companies — Amazon (NASDAQ:AMZN), Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), and Intuitive Surgical (NASDAQ:ISRG) — share the three characteristics I value above all else in my portfolio: a wide and defendable moat, multiple ways of growing their businesses moving forward, and stellar balance sheets.

Top 10 Growth Stocks To Own For 2019: Buffalo Wild Wings Inc.(BWLD)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Dave & Busters Entertainment tripling in value before falling back while small cap upscale gentlemen’s clubs and restaurant owner RCI Hospitality Holdings, Inc (NASDAQ: RICK) began taking off in 2016 and small cap Buffalo Wild Wings (NASDAQ: BWLD) is being acquired by Arby’s Restaurant Group:

  • [By Steve Symington]

    That’s not to say it was a quiet day for every stock on the market. With earnings season ramping up, brewing giant Anheuser-Busch InBev (NYSE:BUD) and restaurant chain Buffalo Wild Wings (NASDAQ:BWLD) served as an exercise in contrast as investors reacted to their respective quarterly reports.

Leave a Reply

Your email address will not be published. Required fields are marked *